Lilly closed at $1,169.60, and one investor narrative puts fair value near $1,477, citing retatrutide's Phase 3 results against pricing pressure.
Recap by typeshit. Full story at Yahoo Finance.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Researchers say the experimental drug produced close to three times the weight loss of current options over the same stretch of time.
The eye clinic says most people on GLP-1 weight loss drugs don't need extra eye checks, but any vision changes are worth noticing.
Loading…